Search

Find out how RNA therapy works, how it differs from gene therapy and why we use it to treat genetic diseases that are currently untreatable.

Find out how ProQR’s stock is trading now and in the past. Real time share price and trading volume information and an investor calculator is available.

When our CEO, Daniel A. de Boer, knew his newborn son had an incurable rare disease, he founded ProQR to help people like his son. Learn more.

An innovative biotech company advancing our proprietary Axiomer RNA-editing platform technology.

Receive an email notification whenever ProQR issues a new press release. Never miss an important update again. Sign up now!

Here you can find our addresses, phone numbers and email addresses for different locations and departments. You can also send us a question via the contact form.

Find all relevant presentations and publications for each of our programs. From review papers to preclinical posters and clinical data presentations at medical conferences.

ProQR invented an entirely new way to treat genetic diseases. Axiomer enables RNA base editing by recruiting ADAR so your own body can treat disease. Learn more here.

Here is a list of the research analysts that cover ProQR Therapeutics (Nasdaq: $PRQR).